Copper(I)-binding properties of de-coppering drugs for the treatment of Wilson disease. α-Lipoic acid as a potential anti-copper agent
Abstract Wilson disease is an autosomal recessive genetic disorder caused by loss-of-function mutations in the P-type copper ATPase, ATP7B, which leads to toxic accumulation of copper mainly in the liver and brain. Wilson disease is treatable, primarily by copper-chelation therapy, which promotes co...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2018-01-01
|
| Series: | Scientific Reports |
| Online Access: | https://doi.org/10.1038/s41598-018-19873-2 |
| _version_ | 1818345630593974272 |
|---|---|
| author | Julia Smirnova Ekaterina Kabin Ivar Järving Olga Bragina Vello Tõugu Thomas Plitz Peep Palumaa |
| author_facet | Julia Smirnova Ekaterina Kabin Ivar Järving Olga Bragina Vello Tõugu Thomas Plitz Peep Palumaa |
| author_sort | Julia Smirnova |
| collection | DOAJ |
| description | Abstract Wilson disease is an autosomal recessive genetic disorder caused by loss-of-function mutations in the P-type copper ATPase, ATP7B, which leads to toxic accumulation of copper mainly in the liver and brain. Wilson disease is treatable, primarily by copper-chelation therapy, which promotes copper excretion. Although several de-coppering drugs are currently available, their Cu(I)-binding affinities have not been quantitatively characterized. Here we determined the Cu(I)-binding affinities of five major de-coppering drugs – D-penicillamine, trientine, 2,3-dimercapto-1-propanol, meso-2,3-dimercaptosuccinate and tetrathiomolybdate – by exploring their ability to extract Cu(I) ions from two Cu(I)-binding proteins, the copper chaperone for cytochrome c oxidase, Cox17, and metallothionein. We report that the Cu(I)-binding affinity of these drugs varies by four orders of magnitude and correlates positively with the number of sulfur atoms in the drug molecule and negatively with the number of atoms separating two SH groups. Based on the analysis of structure-activity relationship and determined Cu(I)-binding affinity, we hypothesize that the endogenous biologically active substance, α-lipoic acid, may be suitable for the treatment of Wilson disease. Our hypothesis is supported by cell culture experiments where α-lipoic acid protected hepatic cells from copper toxicity. These results provide a basis for elaboration of new generation drugs that may provide better therapeutic outcomes. |
| first_indexed | 2024-12-13T17:05:26Z |
| format | Article |
| id | doaj.art-5d926ca94e3f422baf2d72ab51c8f33f |
| institution | Directory Open Access Journal |
| issn | 2045-2322 |
| language | English |
| last_indexed | 2024-12-13T17:05:26Z |
| publishDate | 2018-01-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj.art-5d926ca94e3f422baf2d72ab51c8f33f2022-12-21T23:37:42ZengNature PortfolioScientific Reports2045-23222018-01-01811910.1038/s41598-018-19873-2Copper(I)-binding properties of de-coppering drugs for the treatment of Wilson disease. α-Lipoic acid as a potential anti-copper agentJulia Smirnova0Ekaterina Kabin1Ivar Järving2Olga Bragina3Vello Tõugu4Thomas Plitz5Peep Palumaa6Department of Chemistry and Biotechnology, Tallinn University of TechnologyDepartment of Chemistry and Biotechnology, Tallinn University of TechnologyDepartment of Chemistry and Biotechnology, Tallinn University of TechnologyDepartment of Chemistry and Biotechnology, Tallinn University of TechnologyDepartment of Chemistry and Biotechnology, Tallinn University of TechnologyWilson Therapeutics ABDepartment of Chemistry and Biotechnology, Tallinn University of TechnologyAbstract Wilson disease is an autosomal recessive genetic disorder caused by loss-of-function mutations in the P-type copper ATPase, ATP7B, which leads to toxic accumulation of copper mainly in the liver and brain. Wilson disease is treatable, primarily by copper-chelation therapy, which promotes copper excretion. Although several de-coppering drugs are currently available, their Cu(I)-binding affinities have not been quantitatively characterized. Here we determined the Cu(I)-binding affinities of five major de-coppering drugs – D-penicillamine, trientine, 2,3-dimercapto-1-propanol, meso-2,3-dimercaptosuccinate and tetrathiomolybdate – by exploring their ability to extract Cu(I) ions from two Cu(I)-binding proteins, the copper chaperone for cytochrome c oxidase, Cox17, and metallothionein. We report that the Cu(I)-binding affinity of these drugs varies by four orders of magnitude and correlates positively with the number of sulfur atoms in the drug molecule and negatively with the number of atoms separating two SH groups. Based on the analysis of structure-activity relationship and determined Cu(I)-binding affinity, we hypothesize that the endogenous biologically active substance, α-lipoic acid, may be suitable for the treatment of Wilson disease. Our hypothesis is supported by cell culture experiments where α-lipoic acid protected hepatic cells from copper toxicity. These results provide a basis for elaboration of new generation drugs that may provide better therapeutic outcomes.https://doi.org/10.1038/s41598-018-19873-2 |
| spellingShingle | Julia Smirnova Ekaterina Kabin Ivar Järving Olga Bragina Vello Tõugu Thomas Plitz Peep Palumaa Copper(I)-binding properties of de-coppering drugs for the treatment of Wilson disease. α-Lipoic acid as a potential anti-copper agent Scientific Reports |
| title | Copper(I)-binding properties of de-coppering drugs for the treatment of Wilson disease. α-Lipoic acid as a potential anti-copper agent |
| title_full | Copper(I)-binding properties of de-coppering drugs for the treatment of Wilson disease. α-Lipoic acid as a potential anti-copper agent |
| title_fullStr | Copper(I)-binding properties of de-coppering drugs for the treatment of Wilson disease. α-Lipoic acid as a potential anti-copper agent |
| title_full_unstemmed | Copper(I)-binding properties of de-coppering drugs for the treatment of Wilson disease. α-Lipoic acid as a potential anti-copper agent |
| title_short | Copper(I)-binding properties of de-coppering drugs for the treatment of Wilson disease. α-Lipoic acid as a potential anti-copper agent |
| title_sort | copper i binding properties of de coppering drugs for the treatment of wilson disease α lipoic acid as a potential anti copper agent |
| url | https://doi.org/10.1038/s41598-018-19873-2 |
| work_keys_str_mv | AT juliasmirnova copperibindingpropertiesofdecopperingdrugsforthetreatmentofwilsondiseasealipoicacidasapotentialanticopperagent AT ekaterinakabin copperibindingpropertiesofdecopperingdrugsforthetreatmentofwilsondiseasealipoicacidasapotentialanticopperagent AT ivarjarving copperibindingpropertiesofdecopperingdrugsforthetreatmentofwilsondiseasealipoicacidasapotentialanticopperagent AT olgabragina copperibindingpropertiesofdecopperingdrugsforthetreatmentofwilsondiseasealipoicacidasapotentialanticopperagent AT vellotougu copperibindingpropertiesofdecopperingdrugsforthetreatmentofwilsondiseasealipoicacidasapotentialanticopperagent AT thomasplitz copperibindingpropertiesofdecopperingdrugsforthetreatmentofwilsondiseasealipoicacidasapotentialanticopperagent AT peeppalumaa copperibindingpropertiesofdecopperingdrugsforthetreatmentofwilsondiseasealipoicacidasapotentialanticopperagent |